Carina Seifried

Boehringer Ingelheim (Germany)

Papers

1

Total Citations

30

H-Index

1

About

Carina Seifried is a virologist and biotechnologist whose work bridges the gap between fundamental virology and the practical demands of biopharmaceutical manufacturing. Her primary research focuses on the development of high-throughput, automated assays for the characterization and quality control of virus-based therapeutics, including viral vectors for gene therapy and oncolytic viruses. Seifried’s most notable contribution is the creation of a fully automated, label-free TCID50 assay, which dramatically improves the speed, reproducibility, and objectivity of infectious titer determination—a critical step in the production of safe and effective viral medicines. This work, published in 2021 and already garnering over 30 citations, addresses a long-standing bottleneck in the field by replacing labor-intensive, subjective manual methods with a robust, image-based platform. Her research is instrumental in enabling scalable, GMP-compliant manufacturing processes, directly impacting the translation of novel viral therapeutics from bench to bedside. By integrating automation with classical virology, Seifried is helping to modernize the quality control toolkit for the next generation of biologic drugs.

Research Focus

Key Achievements

1
H-Index
1
Papers
30
Total Citations
30
Avg Citations/Paper
🏆 Most Cited Paper
Automated, label-free TCID50 assay to determine the infectious titer of virus-based therapeutics
30 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 4
🏛 Institutions: Boehringer Ingelheim (Germany)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago